State Street’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-807,443
| Closed | -$1.49M | – | 4810 |
|
|
2023
Q1 | $1.49M | Buy |
807,443
+159,134
| +25% | +$197K | ﹤0.01% | 3423 |
|
|
2022
Q4 | $720K | Sell |
648,309
-4,726
| -0.7% | -$6.73K | ﹤0.01% | 3643 |
|
|
2022
Q3 | $1.53M | Sell |
653,035
-4,884
| -0.7% | -$17.3K | ﹤0.01% | 3487 |
|
|
2022
Q2 | $1.99M | Buy |
657,919
+126,890
| +24% | +$617K | ﹤0.01% | 3480 |
|
|
2022
Q1 | $3.61M | Buy |
531,029
+24,271
| +5% | +$173K | ﹤0.01% | 3332 |
|
|
2021
Q4 | $4.23M | Buy |
506,758
+8,773
| +2% | +$72.3K | ﹤0.01% | 3315 |
|
|
2021
Q3 | $3.7M | Buy |
497,985
+59,220
| +13% | +$367K | ﹤0.01% | 3391 |
|
|
2021
Q2 | $2.98M | Buy |
438,765
+132,486
| +43% | +$1.1M | ﹤0.01% | 3468 |
|
|
2021
Q1 | $3.15M | Sell |
306,279
-22,427
| -7% | -$246K | ﹤0.01% | 3250 |
|
|
2020
Q4 | $2.3M | Sell |
328,706
-6,840
| -2% | -$53.2K | ﹤0.01% | 3308 |
|
|
2020
Q3 | $2.74M | Sell |
335,546
-20,170
| -6% | -$125K | ﹤0.01% | 3071 |
|
|
2020
Q2 | $2.45M | Sell |
355,716
-63,056
| -15% | -$340K | ﹤0.01% | 3096 |
|
|
2020
Q1 | $1.99M | Buy |
418,772
+10,081
| +2% | +$58K | ﹤0.01% | 3074 |
|
|
2019
Q4 | $3.57M | Sell |
408,691
-11,986
| -3% | -$64.8K | ﹤0.01% | 3012 |
|
|
2019
Q3 | $1.4M | Buy |
420,677
+46,608
| +12% | +$187K | ﹤0.01% | 3328 |
|
|
2019
Q2 | $1.85M | Buy |
374,069
+120,174
| +47% | +$638K | ﹤0.01% | 3268 |
|
|
2019
Q1 | $1.57M | Buy |
253,895
+13,016
| +5% | +$62.9K | ﹤0.01% | 3234 |
|
|
2018
Q4 | $812K | Sell |
240,879
-20,110
| -8% | -$93.9K | ﹤0.01% | 3365 |
|
|
2018
Q3 | $1.7M | Buy |
260,989
+5,312
| +2% | +$39.5K | ﹤0.01% | 3306 |
|
|
2018
Q2 | $1.96M | Buy |
255,677
+2,298
| +0.9% | +$33.1K | ﹤0.01% | 3270 |
|
|
2018
Q1 | $5.66M | Buy |
253,379
+71,219
| +39% | +$1.58M | ﹤0.01% | 2737 |
|
|
2017
Q4 | $2.32M | Buy |
182,160
+28,122
| +18% | +$413K | ﹤0.01% | 3130 |
|
|
2017
Q3 | $2.4M | Buy |
154,038
+53,805
| +54% | +$761K | ﹤0.01% | 3122 |
|
|
2017
Q2 | $1.41M | Buy |
100,233
+54,803
| +121% | +$1.17M | ﹤0.01% | 3255 |
|
|
2017
Q1 | $1M | Buy |
+45,430
| New | +$963K | ﹤0.01% | 3261 |
|
Other funds holding JNCE
State Street's JNCE Position: Q2 2023 in Review
State Street sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 807,443 shares — an estimated $1.49M sold.
State Street first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $5.66M in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- State Street reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- State Street sold 807,443 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.49M.
- State Street first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- State Street's Jounce Therapeutics, Inc. Common Stock position peaked at $5.66M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.